Investor Relations
Our Investment Story
Collateral Medical Pvt. Ltd. is a founder-led, Mumbai-based healthcare company with 15 years of profitable, disciplined growth. From building one of India's widest medical device distribution networks to pioneering digital and e-commerce channels for healthcare — and now developing proprietary AI-assisted diagnostic devices — ColMed has consistently been ahead of the curve.
We take institutional investment only when it accelerates a clear strategic objective. We have honoured every obligation, to every partner, on time. Our capital history is clean. Our governance is independently certified and externally rated.
🏆 New investors in ColMed join a company that has already earned the trust of some of the world's most rigorous institutional capital allocators.
Current Equity Investors
Carpediem Capital — India
A leading Indian private equity fund focused on the India Consumption growth story, backing emerging SME leaders with significant minority and control investments. Carpediem's investment in ColMed reflects conviction in the long-term structural growth of healthcare access and medical device adoption across India.
Vincit (Foundation Private Equity) — GIFT City, India
A GIFT City-based private equity fund backed by Foundation PE, Singapore, with a focus on scalable, impact-aligned businesses. Vincit's presence in India's premier international financial services centre reflects its commitment to the India growth story and conviction in ColMed's positioning at the intersection of healthcare access, technology innovation, and sustainable commercial growth.
Our Track Record with Institutional Capital
Before our current equity structure, ColMed was evaluated and backed by some of the world's most stringent institutional investors and development finance bodies. Every obligation was fulfilled in full and on schedule.
|
The UK FCDO — the majority LP in Samridhi Fund — applies exceptionally high standards of governance, impact measurement, and financial due diligence. Their selection of ColMed, and the clean, timely exit, reflects the level of governance and financial discipline that ColMed operates to.
Why ColMed, Why Now
- ₹80,000+ crore market growing at 15%+ CAGR
- Accelerating chronic disease burden — diabetes, liver disease, cardiovascular, neurological
- Massive diagnostic gap between urban and rural India — 700+ districts need affordable devices
- Government import substitution mandate creating tailwinds for indigenous MedTech
- Digital health and AI creating entirely new care delivery models
- 700+ district distribution network and 15 years of clinical and commercial relationships
- R&D partnerships with CSIR labs and IIT Bombay; clinical validation at ILBS and Fortis
- ColMed Healthtech Pvt. Ltd. incubated at SINE IIT Bombay — industrial design-led healthcare innovation
Our Investment Posture
🤝 ColMed is not conducting an active fundraise. We are selectively open to conversations with strategic investors who can meaningfully accelerate our proprietary device pipeline or digital health platform — and who share our commitment to making high-quality healthcare accessible across India.
Strategic & Financial Investors
- Healthcare sector expertise, clinical networks, or regulatory experience in India or globally
- Access to international markets for Indian-made medical devices
- Technology, AI, or digital health capability and networks
- Distribution or go-to-market presence in healthcare across India or Asia
Mission-Driven & Impact Investors
ColMed's work is deeply rooted in chronic disease management and the health and wellbeing of India's most underserved populations. We welcome conversations with investors, foundations, family offices, and development finance institutions who have a particular focus on:
- Chronic disease — liver disease (hepatology), diabetes, respiratory conditions, and the growing burden of NCDs across India
- Women's health — maternal health, reproductive health, cervical cancer screening, anaemia, osteoporosis, and conditions that disproportionately affect women in India
- Child health — paediatric diagnostics, developmental screening, nutrition, and early intervention
- Elder care & healthy ageing — fall prevention, sarcopenia, cognitive decline, and India's rapidly ageing population
🌱 If your capital is guided by the belief that quality healthcare should reach every Indian patient — regardless of geography, income, or age — we would like to speak with you.
ESG & Impact
- 700+ districts covered — healthcare access beyond metro India
- 1,000+ reseller partners creating healthcare livelihoods across the country
- 48% of employees from disadvantaged socioeconomic backgrounds
- 25% female representation at management level
- 40% reduction in electricity consumption since 2020
- CareEdge ESG Rating: 4/5 — full reports available at colmed.in/esg